Everest Medicines Ltd Financials

Market Capitalization HK$16.65 Billion as of Jan. 1, 2026

Valuations Metrics as of Jan. 3, 2026

Trailing PE	658.75
Forward PE	100.23
Price to Sales TTM	HK$15.73
Price to Book MRQ	HK$2.84
Enterprise to Revenue	13.58
Enterprise to EBITDA	-19.44

Financial Reports as of Jun. 30, 2020

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2020-06-30
Profit Margin	-77.38%
Operating Margin	-62.04%
Return on Assets TTM	-21.00%
Return on Equity TTM	-25.57%

Income Statement

Revenue TTM	HK$946,610,746
Revenue per Share TTM	HK$2.63
Quarterly Revenue Growth	48.00%
Gross Profit TTM	HK$664,082,213
EBITDA	HK$-661,263,370
Net Income to Common TTM	HK$-732,519,048
Diluted EPS TTM	HK$-2.26
Quarterly Earnings Growth YoY	%

Balance Sheet

Total Cash MRQ	HK$1,763,496,803
Total Cash per Share MRQ	HK$4.84
Total Debt MRQ	HK$
Total Debt to Equity MRQ	18.72
Current Ratio MRQ	5.46
Book Value per Share MRQ	HK$13.34

Cash Flow

Operating Cash Flow TTM	HK$-495,986,456
Levered Free Cash Flow TTM	HK$-1,157,988,172

1952 Stock Info as of Jan. 3, 2026

Stock Statistics

Shares Outstanding	327,427,567
Float Shares	245,983,234
Avg 10 Volume	5,041,568
Avg 30 Volume	None
Shares Short	None
Short Ratio
Short % of Shares	%
% Held by Insiders	0.75%
% Held by Institutions	35.88%

Stock Price Summary

Beta	1.85
Fifty Two Week Low	HK$36.30
Fifty Two Week High	HK$77.55
Fifty Two Week Change	-39.18%
Day 50 MA	HK$46.19
Day 200 MA	HK$54.64

Dividends and Splits

Forward Annual Dividend Rate	HK$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	HK$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date